1. Asian Pacific Association for the Study of the Liver clinical practice guidelines on liver transplantation

   • Dong-Sik Kim
   • Young-In Yoon
   • for Asian Pacific Association for Study of Liver (APASL)

   Guidelines 28 February 2024 Pages: 299 - 383

   

2. Chinese guideline for the diagnosis and treatment of drug-induced liver injury: an update

   • Yimin Mao
   • Shiwu Ma
   • the Technology Committee on DILI Prevention, Management, Chinese Medical Biotechnology Association; Study Group on Drug-Induced Liver Disease, Chinese Society of Hepatology, Chinese Medical Association

   Guidelines 24 February 2024 Pages: 384 - 419

   

3. Nomograms should be noted

   • Shuntaro Obi
   • Masao Omata

   Editorial 01 March 2024 Pages: 420 - 421

   

4. Artificial intelligence in liver imaging: methods and applications

   • Peng Zhang
   • Chaofei Gao
   • Xiaolong Qi

   Review Article 20 February 2024 Pages: 422 - 434

   

5. Functional cure is associated with younger age in children undergoing antiviral treatment for active chronic hepatitis B

   • Min Zhang
   • Jing Li
   • Fu-Sheng Wang

   Original Article Open access 20 February 2024 Pages: 435 - 448

   

6. Preventing viral relapse with prophylactic tenofovir in hepatitis B carriers receiving chemotherapy: a phase IV randomized study in Taiwan

   • Chao-Wei Hsu
   • Shin-Cheh Chen
   • Chau-Ting Yeh

   Original Article 20 February 2024 Pages: 449 - 460

   

7. An algorithm for simplified hepatitis C virus treatment with non-specialist care based on nation-wide data from Taiwan

   • Ming-Lung Yu
   • Chi‐Ming Tai
   • Cheng-Yuan Peng

   Original Article Open access 21 January 2024 Pages: 461 - 475

   

8. Planning, implementing, and evaluating Hepatitis C virus elimination via collaborative community-based care cascade: age–period–cohort model for estimating demand from antecedent anti-HCV survey

   • Ting-Yu Lin
   • Hsiao-Hsuan Jen
   • Yen-Po Yeh

   Original Article Open access 21 November 2023 Pages: 476 - 485

   

9. Characteristics of microbiome-derived metabolomics according to the progression of alcoholic liver disease

   • Raja Ganesan
   • Haripriya Gupta
   • Ki Tae Suk

   Original Article 31 March 2023 Pages: 486 - 499

   

10. New prognostic model for hospitalized patients with alcoholic cirrhosis and Maddrey’s discriminant function <32

    • Tae Hyung Kim
    • Hyung Joon Yim
    • The Korean Acute-on-Chronic Liver Failure (KACLiF) Study Group

    Original Article 13 October 2023 Pages: 500 - 508

    

11. ChIP-seq analysis found IL21R, a target gene of GTF2I–the susceptibility gene for primary biliary cholangitis in Chinese Han

    • Ziyan Wu
    • Haolong Li
    • Yongzhe Li

    Original Article 15 September 2023 Pages: 509 - 516

    

12. Proteome-wide Mendelian randomization highlights AIF1 and HLA-DQA2 as targets for primary sclerosing cholangitis

    • Lanlan Chen
    • Yuexuan Zhao
    • Guoyue Lv

    Original Article 11 November 2023 Pages: 517 - 528

    

13. Dairy products intake and prevalence, incidence, and recovery of non-alcoholic fatty liver disease in Chinese population

    • Yurou Xu
    • Youyi Wang
    • Xing Liu

    Original Article 26 February 2024 Pages: 529 - 539

    

14. Incidence and predictors of hepatocellular carcinoma in NAFLD without diagnosed cirrhosis: a nationwide real-world U.S. study

    • Daniel Q. Huang
    • Sally Tran
    • Mindie H. Nguyen

    Original Article 11 December 2023 Pages: 540 - 549

    

15. OHCCPredictor: an online risk stratification model for predicting survival duration of older patients with hepatocellular carcinoma

    • Juntao Tan
    • Yue Yu
    • Xiaoxin Wu

    Original Article Open access 17 April 2023 Pages: 550 - 567

    

16. Hepatocellular carcinoma (HCC) tumor microenvironment is more suppressive than colorectal cancer liver metastasis (CRLM) tumor microenvironment

    • Sara Santagata
    • Giuseppina Rea
    • Stefania Scala

    Original Article Open access 04 May 2023 Pages: 568 - 581

    

17. Distinctly altered lipid components in hepatocellular carcinoma relate to impaired T cell-dependent antitumor immunity

    • Xue Cheng
    • Wei Wang
    • Xiufang Weng

    Original Article 12 October 2023 Pages: 582 - 594

    

18. TACE plus tyrosine kinase inhibitors and immune checkpoint inhibitors versus TACE plus tyrosine kinase inhibitors for the treatment of patients with hepatocellular carcinoma: a meta-analysis and trial sequential analysis

    • Jiaxi Liu
    • Peng Wang
    • Haibo Shao

    Original Article 16 October 2023 Pages: 595 - 609

    

19. Fibroblast growth factor inhibition by molecular-targeted agents mitigates immunosuppressive tissue microenvironment in hepatocellular carcinoma

    • Hiroyuki Suzuki
    • Hideki Iwamoto
    • Takumi Kawaguchi

    Original Article Open access 21 October 2023 Pages: 610 - 622

    

20. A multicenter propensity score analysis of significance of hepatic resection type for early-stage hepatocellular carcinoma

    • Shi-Chuan Tang
    • Kai-Ling Zhang
    • Yong-Yi Zeng

    Original Article 25 October 2023 Pages: 623 - 635

    

21. Transferrin receptor 1 promotes hepatocellular carcinoma progression and metastasis by activating the mTOR signaling pathway

    • Fu Wang
    • Wei-Qi Xu
    • Ji-Min Zhu

    Original Article 20 November 2023 Pages: 636 - 650

    

22. The TAE score predicts prognosis of unresectable HCC patients treated with TACE plus lenvatinib with PD-1 inhibitors

    • Zhen-Xin Zeng
    • Jia-Yi Wu
    • Mao-Lin Yan

    Original Article 01 December 2023 Pages: 651 - 660

    

23. Diagnostic yield and novel candidate genes by next generation sequencing in 166 children with intrahepatic cholestasis

    • Yucan Zheng
    • Hongmei Guo
    • Zhifeng Liu

    Original Article 14 June 2023 Pages: 661 - 672

    

24. Skeletal muscle alterations indicate poor prognosis in cirrhotic patients: a multicenter cohort study in China

    • Xin Zeng
    • Zhi-Wen Shi
    • Wei-Fen Xie

    Original Article 18 June 2023 Pages: 673 - 687

    

25. Prevalence and impact on the outcome of myosteatosis in patients with cirrhosis: a systematic review and meta-analysis

    • Aikaterini Kamiliou
    • Vasileios Lekakis
    • Evangelos Cholongitas

    Original Article Open access 08 February 2024 Pages: 688 - 699

    

26. Response to letter to editor for risk of dyslipidemia in chronic hepatitis B patients taking tenofovir alafenamide: a systematic review and meta-analysis

    • Jin Wook Park
    • Jeong-Ju Yoo
    • Young Seok Kim

    Letter to the Editor 29 February 2024 Pages: 700 - 701

27. Comments on: Risk of dyslipidemia in chronic hepatitis B patients taking tenofovir alafenamide: a systematic review and meta-analysis

    • Yan Wang
    • Xiu Sun
    • Qi Mei

    Letter to the Editor Open access 02 March 2024 Pages: 702 - 703

28. Is lenvatinib in combination with transarterial chemoembolization benefit for unresectable hepatocellular carcinoma (uHCC)? The age interference needs to be eliminated

    • Sai Li
    • Yong Li

    Letter to the Editor 09 November 2023 Pages: 704 - 705

29. Editorial: The safety profile of endoscopic variceal ligation in patients with esophageal varices. Authors’ reply

    • N. Pfisterer
    • M. Schwarz
    • T. Reiberger

    Letter to the Editor 23 December 2023 Pages: 706 - 707

30. Abstracts

    • Shiv Sarin

    Abstracts 05 April 2024 Pages: 708 - 815